Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

First Posted Date
2022-08-08
Last Posted Date
2022-10-06
Lead Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Target Recruit Count
400
Registration Number
NCT05491304
Locations
🇨🇳

The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

ChiCGB vs BEAM in High-risk or R/R Lymphomas

First Posted Date
2022-07-20
Last Posted Date
2022-07-25
Lead Sponsor
Sichuan University
Target Recruit Count
306
Registration Number
NCT05466318
Locations
🇨🇳

Chengdu Third People's Hospital, Chendu, Sichuan, China

🇨🇳

People's Hospital of Deyang City, Deyang, Deyang, China

🇨🇳

West China Hospital, Sichuan University, Chendu, Sichuan, China

and more 8 locations

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

First Posted Date
2022-07-12
Last Posted Date
2024-04-23
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT05453500
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

First Posted Date
2022-06-16
Last Posted Date
2022-06-16
Lead Sponsor
Zhongda Hospital
Target Recruit Count
20
Registration Number
NCT05422183
Locations
🇨🇳

Zhongda Hospital, Nanjing, Jiangsu, China

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

First Posted Date
2022-05-25
Last Posted Date
2024-11-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT05389423
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

First Posted Date
2022-05-20
Last Posted Date
2024-02-20
Lead Sponsor
Fundación GECP
Target Recruit Count
85
Registration Number
NCT05384015
Locations
🇪🇸

Hospital General Universitario de Valencia, Valencia, Spain

🇪🇸

ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain

and more 15 locations

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

First Posted Date
2022-05-20
Last Posted Date
2023-10-16
Lead Sponsor
Centre Oscar Lambret
Target Recruit Count
28
Registration Number
NCT05384821
Locations
🇫🇷

CHU de MONTPELLIER - Hôpital Arnaud de Villeneuve, Montpellier, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

CHRU NANCY - Hôpital d'Enfants, Vandœuvre-lès-Nancy, France

and more 13 locations

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

First Posted Date
2022-05-18
Last Posted Date
2022-05-18
Lead Sponsor
Zhejiang University
Target Recruit Count
24
Registration Number
NCT05379647
Locations
🇨🇳

The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

First Posted Date
2022-05-06
Last Posted Date
2024-12-19
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT05364424
Locations
🇺🇸

Chao Family Comprehensive Cancer Center UCI, Orange, California, United States

🇺🇸

Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States

🇺🇸

The University of Chicago, Chicago, Illinois, United States

and more 6 locations

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

First Posted Date
2022-05-04
Last Posted Date
2024-07-25
Lead Sponsor
Amgen
Target Recruit Count
340
Registration Number
NCT05361395
Locations
🇺🇸

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Christiana Care Health Services, Newark, Delaware, United States

🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

and more 41 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy